misleading media syringe buying
Don't be part of that poor mob selling their stock on journalist jive. Even JB Were which doesn't cover the stock are making silly negative projections.
This stock will not be going to $2. The turnover is light and the stock is embedded with one major holder and true believer pharmacy owners.
This company despite its woes will pay a 9.5c dividend from profit. It supplies 2500 customers including its 953 chemists including discounter priceline and the House retail chain. It has two manufacturing plants but does not manufacture generic prescription drugs.
There are innumerable scenarios that would cause its price to soar let alone its profitability.
The logistics factor is well recognised and the duplication of pharmacy supply lorries screams for consolidation.
Remember HVN at $3.55 and limited growth prospects pays an 8c dividend.
At API so much can be fixed and there is volatile upside.
Don't be fooled by the media. The company is not kidding when it says that a number of parties are interested in ownership of its assets.
This company is a target. The latest story is that Metcash will take them out. If so the stock price would rise $1 a more.
Remember this stock was $3 for a long time. I have bought a lot and am happy to keep buying at current levels. It's a bit sad really to see the small sell parcels falling to big buy orders.
Oh well it's a living.
API Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
